Olivia Delene Weber

USPTO Granted Patents = 22 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 78(Granted Patents)

Company Filing History:

9 out of 18

Abide Therapeutics, Inc.

Lundbeck La Jolla Research Center, Inc.

patents

4. 1 out of 1,186

The Scripps Research Institute

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12378219 - Crystalline forms of a MAGL inhibitor (2025-08-05),

2. 12318383 - Dual MAGL and FAAH inhibitors (2025-06-03),

3. 12258340 - Pyrazole MAGL inhibitors (2025-03-25),

4. 11655217 - Pyrazole MAGL inhibitors (2023-05-23),

5. 11434222 - MAGL inhibitors (2022-09-06),

6. 11161856 - Spirocycle compounds and methods of making and using same (2021-11-02),

7. 11149037 - Pyrazole MAGL inhibitors (2021-10-19),

8. 11142526 - Spirocycle compounds and methods of making and using same (2021-10-12),

9. 11129827 - Dual MAGL and FAAH inhibitors (2021-09-28),

10. 10927105 - Pyrazole MAGL inhibitors (2021-02-23),

11. 10899737 - Piperazine carbamates and methods of making and using same (2021-01-26),

12. 10781211 - Spirocycle compounds and methods of making and using same (2020-09-22),

13. 10519134 - Pyrazole compounds and methods of making and using same (2019-12-31),

14. 10385057 - Pyrazole compounds and methods of making and using same (2019-08-20),

15. 10350205 - Dual MAGL and FAAH inhibitors (2019-07-16),

Title: Olivia Delene Weber: A Pioneering Inventor in the Field of Pharmaceutical Innovations

Introduction: Olivia Delene Weber is an esteemed inventor based in San Diego, CA, recognized for her significant contributions to pharmaceutical sciences. With a remarkable portfolio of 19 patents, she has consistently pushed the boundaries of innovation in medicinal chemistry, particularly in the development of compounds for the treatment of pain and various diseases.

Latest Patents: Among her latest patents, Olivia has developed pyrazole compounds, described as effective modulators of monoacylglycerol lipase (MAGL). These pharmaceutical compositions are noteworthy for their potential in pain management. Additionally, she has patented a class of substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds, which serve as inhibitors of MAGL, offering promising therapeutic avenues for diseases that can benefit from such inhibition.

Career Highlights: Olivia's career has flourished at leading research institutions, notably at Abide Therapeutics, Inc., where she played a pivotal role in advancing therapeutic platforms focused on novel compounds. She has also contributed to innovative research at Lundbeck La Jolla Research Center, Inc., where her work has significantly benefited drug development initiatives.

Collaborations: Throughout her career, Olivia has collaborated with esteemed colleagues, including Cheryl A. Grice and Justin S. Cisar. Their collective expertise has enhanced the research environment, fostering creativity and innovation that ultimately translates into impactful inventions.

Conclusion: Olivia Delene Weber stands as a prominent figure in the pharmaceutical industry, with a commitment to advancing medical science through her inventive spirit. Her patents reflect a dedication to improving patient outcomes and demonstrate her vital role in the innovation landscape of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.